A day after cutting the price range on its initial public offering, medical device company Amedica wound up pricing the IPO well under even the low end of its $8-$10 range, bringing in about $20.1 million from its $5.75-per-share offering of 3.5 million shares.
Initial Public Offering (IPO)
Amedica lowers IPO price range, boosts shares on offer
Medical device company Amedica lowered the price range for its impending initial public offering, but said it would put more shares on offer.
Semler Scientific lowers IPO price
Semler Scientific is lowering its IPO price, now seeking $10 million instead of the previous $15 million it desired.
Portland, Ore.-based Semler specializes in medical risk-assessment. The company’s flagship product is the FloChec, which tracks blood flow in lower and upper extremities. The device is cleared by the FDA, according to the company’s website.
Inogen plans for $75M IPO
Inogen narrowed the price range for the initial public offering it registered late last year, saying it expects to price the IPO at $16 to $18 per share.
That would make the 4.4-million-share offering worth $70.6 million to $79.4 million; if the shares sell at the midpoint, Inogen would raise about $75.0 million.
Amedica looks to $35M U.S. IPO
Medical device company Amedica said it’s planning to put up nearly 3.2 million shares at $10 to $12 apiece in an initial public offering in the U.S.
Salt Lake City-based Amedica, which makes silicon nitride-based biomaterials for medical devices, said it plans to trade under the AMDA symbol on the NASDAQ exchange.
At the midpoint of the proposed offering range, Amedica would have an initial market capitalization of $143 million.
Rehab robots: Ekso Bionics goes public, raises $20.6M
California robotics company Ekso Bionics (OTCBB:EKSO) raised $20.6 million through a private placement offering and a reverse merger that made the company a wholly owned subsidiary of Ekso Bionics Holdings.
Spinal: K2M finally goes public
Leesburg, Va.-based K2M Group Holdings announced today that it confidentially filed registration statements to launch an initial public offering of its common stock.
K2M, long the largest private spine implant company, did not provide details on potential timing, but said that the number of shares and price range for stock has yet to be determined.
London’s Lombard Medical seeks U.S. IPO
The medtech tax will be repealed, and other predictions for 2014
As we put a ribbon on 2013, another tumultuous year for the medical device industry, it’s time to check the tea leaves for what medtech might expect in 2014.
These predictions are based on the 2,500 or so stories we’ve written this year about the medical device space, as well as conversations we’ve had with hundreds of industry leaders about their thoughts, concerns, annoyances and triumphs.
Prediction #1: The medical device tax will not survive 2014
Next year looks good for IPOs
Initial public offerings hit decade-long highs in 2013, a trend that should continue in 2014, according to Renaissance Capital.
Coming off of their best year since 2000, U.S. IPOs should fare well in the new year, based on "a building backlog of IPOs and economic indicators continuing to show signs of improvement," according to the IPO investment advisor.
IPOs reach pre-bubble highs in 2013
The market for initial public offerings in the U.S. hit a high this year not seen since the tech bubble burst in the early 2000s, with more than 222 IPOs expected before the end of 2013.
The 6 offerings priced Dec. 11 brought the annual IPO total to 218, beating the post-bubble peak of 217 reached in 2004 and eclipsing the most recent high of 213 in 2007, according to Renaissance Capital.